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Abstract: Respiratory viruses infections caused by influenza viruses, human parainfluenza 
virus (hPIV), respiratory syncytial virus (RSV) and coronaviruses are an eminent threat for 
public health. Currently, there are no licensed vaccines available for hPIV, RSV and 
coronaviruses, and the available seasonal influenza vaccines have considerable limitations. 
With regard to pandemic preparedness, it is important that procedures are in place to 
respond rapidly and produce tailor made vaccines against these respiratory viruses on short 
notice. Moreover, especially for influenza there is great need for the development of a 
universal vaccine that induces broad protective immunity against influenza viruses of 
various subtypes. Modified Vaccinia Virus Ankara (MVA) is a replication-deficient viral 
vector that holds great promise as a vaccine platform. MVA can encode one or more 
foreign antigens and thus functions as a multivalent vaccine. The vector can be used at 
biosafety level 1, has intrinsic adjuvant capacities and induces humoral and cellular 
immune responses. However, there are some practical and regulatory issues that need to be 
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addressed in order to develop MVA-based vaccines on short notice at the verge of a 
pandemic. In this review, we discuss promising novel influenza virus vaccine targets and 
the use of MVA for vaccine development against various respiratory viruses. 
Keywords: modified vaccinia virus ankara; vaccine development; influenza virus; 
respiratory syncytial virus; parainfluenza virus; coronavirus 
 
1. Introduction 
Respiratory viruses, such as seasonal and pandemic influenza viruses, human parainfluenza virus 
(hPIV), respiratory syncytial virus (RSV) and coronaviruses, cause substantial burden of disease 
globally. These pathogens cause respiratory tract infections, mainly in young children, the elderly and 
immunocompromised individuals. In contrast to seasonal influenza, currently no licensed RSV and 
hPIV vaccines are available.  
For influenza, it is recommended to annually vaccinate people at risk to protect them against 
infection with seasonal influenza viruses. However, as a result of selective pressure exerted by 
virus-specific antibodies induced by previous infections and/or vaccination, seasonal influenza viruses 
accumulate mutations in the antigenic sites of the two main surface proteins: hemagglutinin (HA) and 
neuraminidase (NA). Consequently, antigenic drift variants emerge that evade host immunity. 
Occasionally, avian or swine influenza viruses are introduced into the human population. Since 
neutralizing antibodies to these novel viruses are virtually absent, the human population at large is 
susceptible to infection. Last year alone, several avian influenza viruses caused human infections. 
From February 2013 to February 2014, 335 human cases of infection with H7N9, of which some 
viruses display signs of adaptation to humans, have been reported [1,2]. One hundred and twelve of 
these cases had a fatal outcome [1]. Although sustained human-to-human transmission of these viruses 
has not been reported, it is possible that they acquire this ability with just a few mutations as was 
shown experimentally for H5N1 viruses in ferrets [3]. In addition, human cases of infections with 
avian viruses of the H10N8 and H9N2 subtype have been reported, some with a fatal outcome [1]. If 
one of these viruses becomes transmissible from human-to-human, it can cause a widespread outbreak 
that could evolve into an influenza pandemic with considerable morbidity and mortality.  
In terms of pandemic preparedness, procedures should be in place to respond rapidly and produce 
tailor made vaccines on short notice. Furthermore, there is a need for the development of universal 
influenza vaccines that induce broad protective immunity against human influenza viruses and 
potentially pandemic viruses of various subtypes.  
2. Targets for Influenza Vaccine Development 
2.1. Conventional Influenza Vaccine 
Currently, trivalent inactivated vaccines are most commonly used to protect risk groups against 
seasonal influenza virus infection. These vaccines contain components of three virus strains responsible 
for epidemic outbreaks: H1N1 and H3N2 influenza A viruses and an influenza B virus [1,4]. Recently, 
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quadrivalent vaccines have become available that contain an additional, antigenically different 
influenza B virus component [1]. These vaccines aim at the induction of virus-neutralizing antibodies 
against HA and NA.  
In order for the vaccines to be effective, it is of great importance that the vaccine strains 
antigenically match the epidemic strains. Therefore, the World Health Organization makes a 
recommendation for vaccine strains twice a year based on the strains that are most likely to circulate 
next season [1]. Using these viruses, whole inactivated vaccines, split virion vaccines or subunit 
vaccines are prepared. In addition to these inactivated influenza vaccines, also live-attenuated vaccines 
are available [4]. 
For decades, the use of seasonal influenza vaccines has helped to reduce influenza-related 
morbidity and mortality [5]. However, the preparation and use of current inactivated influenza 
vaccines has some limitations. First, if the vaccine strains do not match the epidemic influenza strains 
antigenically, vaccine effectiveness will be reduced. In addition, the seasonal influenza vaccine will 
offer little or no protection against influenza viruses of a novel subtype with pandemic potential. 
Second, the vaccine production capacity, even of all manufacturers combined, is limited. Especially in 
the case of a pandemic outbreak, the vaccine needs to become globally available in a short period of 
time [6]. Third, it takes too long for vaccines to become available using conventional production 
methods. For example, during the 2009 H1N1 pandemic outbreak it took six months before 
vaccination campaigns started in most countries, often after the peak of the pandemic [7]. Fourth, 
subjects in the high-risk groups may not respond optimally to vaccination and thus the vaccine is least 
effective in the people who need it most. Finally, inactivated influenza vaccines inefficiently induce 
virus-specific CD8
+
 T cells, which contribute to cross-protective immunity [8,9].  
These limitations underscore the need for the development of novel vaccine production platforms 
and novel vaccine candidates that not only allow for rapid availability of vaccines in the face of an 
emerging pandemic, but that also may be used for the induction of broad protective immunity. Several 
approaches, at different stages of development, are under investigation in order to achieve the ultimate 
goal: a universal influenza vaccine. Here, we describe how the immunogenic potential of the different 
influenza virus antigens is assessed in the context of universal influenza vaccine development. 
2.2. Induction of HA Stalk-Specific Antibodies 
The antibody response induced by influenza virus infection or vaccination is mainly directed 
against the surface protein HA. These antibodies can have neutralizing activity by preventing virus 
attachment to the host cell or the post attachment fusion event. HA consists of two domains: a globular 
head-domain that is highly variable within and between subtypes and a more conserved stalk-domain. 
Based on phylogenetic analysis of the nucleotide sequence of HA, influenza A viruses can be divided 
in group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17) and group 2 (H3, H4, H7, H10, H14, 
H15) viruses [10]. 
Broadly neutralizing antibodies specific for the head-domain have been described [11–16]. 
However, considering the high mutation rate of this domain, eliciting an antibody response specific for 
the stalk-domain has more potential to induce heterosubtypic immunity. HA stalk-specific antibodies 
are induced after influenza virus infection or vaccination [11,17–20]. However, the magnitude of the 
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stalk-specific antibody response varies considerably between individuals. Moreover, given the low 
frequency of stalk-specific B cells it is unlikely that the antibody levels induced upon influenza virus 
infection afford protection [11,20].  
It has been shown that passive immunization with stalk-specific antibodies affords protection 
against infection with a heterologous influenza virus in mice and ferrets [11,15,18,21–26] (reviewed 
in [10]). Several HA stalk-based vaccine strategies have been described, including sequential 
vaccination with a chimeric HA that contains a conserved stalk but a head-domain of different 
influenza subtypes [20,26–30]. Furthermore, modification of the head-domain by the introduction of 
extra glycosylation sites to shield the head-domain from recognition by virus-specific B-cells in favor 
of an antibody response to the stalk-domain [31] also seems a promising strategy to induce a robust 
anti-stalk antibody response. However, stalk-reactive antibodies specific for both group 1 and group 2 
HA-expressing influenza A viruses are rare [32]. Therefore, a universal vaccine that induces or boosts 
a stalk-specific antibody response would probably require components of both group 1 and group 2 
HA proteins and influenza B viruses. 
2.3. Antibody Response against NA and M2 
The second surface protein NA enables the release of progeny virions from the host’s cell surface. 
Upon an influenza virus infection, NA-specific antibodies are induced, which can be boosted by 
vaccination with trivalent influenza vaccines [33]. NA-specific antibodies are not able to exert 
heterosubtypic immunity to the extent of HA stalk-specific antibodies. Nevertheless, it has been shown 
that anti-NA antibodies can provide some intrasubtypic immunity [34]. In contrast to HA, these 
antibodies do not prevent virus infection but rather hamper release of newly formed virus particles [35]. 
Not only NA-specific antibodies elicited through natural infection, but also NA antibodies induced 
by immunization can provide intrasubtypic protection. Vaccination with a DNA plasmid expressing 
NA has been shown to provide protection against infection with a structurally similar influenza 
virus [36,37]. Given the narrow range of protection of this NA-specific antibody response, a 
stand-alone NA-based vaccine would not be the most attractive candidate for universal influenza 
vaccine development. However, the addition of NA to an HA component can improve the 
virus-specific antibody response [38]. 
The third and minor surface protein is matrix protein 2 (M2), which forms ion channels in the viral 
envelope. M2, more specifically the M2 ectodomain (M2e), is considered a good candidate for 
universal influenza vaccine development because it is relatively conserved among influenza A 
viruses [39]. Antibodies specific for M2 are unable to neutralize the virus due to their inability to bind 
the protein on the virion surface. However, antibodies can bind to M2 when it is exposed on the 
surface of infected host cells. These antibodies mediate killing of the infected cells by 
antibody-dependent cellular cytotoxicity (ADCC), most likely by natural killer (NK) cells [40]. 
M2-specific antibodies may also opsonize infected cells for phagocytosis by macrophages [41,42].  
Due to its poor immunogenicity, vaccine development based on M2 protein is challenging. 
However, if the M2-based vaccine is adjuvanted, a robust antibody response can be induced [43]. 
Several M2-based influenza vaccine candidates have been described and validated in various animal 
models, including DNA constructs [44], virus-like particles (VLPs) [40–42,45] and viral vectors [46]. 
Viruses 2014, 6 2739 
 
 
It has been shown that M2-based vaccines can provide protection against infection with a heterologous 
virus [41,46,47]. Moreover, even six months after vaccination mice were protected from a homologous 
challenge infection [41], indicating that an M2-based vaccine can provide long-term protection. 
Currently, M2-based vaccines are tested in clinical trials [48]. However, M2-specific antibodies alone 
cannot provide sterile immunity [39]. Therefore, combining M2 with another influenza antigen might 
induce a better protective immune response [49].  
2.4. Broadly Reactive T Cell Responses against Influenza Viruses 
During an influenza virus infection antigen presenting cells (APCs), predominantly dendritic cells 
(DCs), process viral proteins into peptides for presentation to naïve T cells. Upon recognition of these 





 naïve T cells into effector cells. A second signal from a co-stimulatory 
molecule is required to prevent abortive clonal expansion. Activated T cells migrate to the lungs where 
they recognize and eliminate infected epithelial cells. When the infection is cleared, two types of 
memory T cells are established: long lived central memory T cells and effector memory T cells [50]. 
It was already recognized over30 years ago that conserved internal influenza virus proteins, like the 
nucleoprotein (NP) and the matrix 1 (M1) protein, are targets for CD8
+
 cytotoxic T lymphocytes 
(CTLs) that consequently cross-react with influenza viruses of different subtypes [51–54]. Infections 
with seasonal influenza virus induce CTLs that even cross-react with influenza viruses of avian or 
swine origin [55–59]. It is now generally accepted that virus-specific CD8
+
 T cells play an important 
role in cross-protective immunity [60]. More recently, it has been demonstrated both in animal models 
and humans that also CD4
+
 T helper cells contribute to cross-protective immunity [61–65]. Upon 
infection with heterologous influenza viruses, cross-reactive anamnestic T cell responses contribute to 
accelerated clearance of infection and reduction of clinical symptoms [66,67]. 
Influenza vaccines aiming at the induction of virus-specific T cells have mainly targeted the internal 
proteins NP and M1. These can be delivered as protein, peptide-carrier conjugate, VLP, DNA plasmid 
or by viral vectors [68]. However, also other relatively conserved influenza virus proteins might be 
considered for the induction of cross-reactive T cell responses, like the polymerase subunits (PA, PB1 
and PB2). 
2.5. Universal Influenza Vaccine 
As described above, there are several promising targets for the development of a universal influenza 
vaccine and several vaccination strategies are being evaluated. Given that not only virus-specific 
antibodies but also T cells contribute to (cross-)protective immunity, it is of importance that a 
universal influenza vaccine activates both arms of the adaptive immune system. In this respect, the use 
of viral vectors for the delivery of viral proteins has advantages over conventional vaccines and holds 
promise. Overexpression of viral proteins potentially increases their immunogenicity. Furthermore, the 
use of a live vector allows de novo synthesis of viral proteins in the cytosol of antigen presenting cells 
and thus facilitates antigen processing and presentation to virus-specific CD8
+
 T cells. Alternatively, 
cross-priming may result in the activation of these cells. Thus, vector vaccines may not only induce 
virus-specific antibody responses but also induce cell-mediated immune responses. Moreover, the 
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antigens of interest are expressed in their native conformation, thus inducing antibodies of the proper 
specificity. Last but not least, viral vector vaccines can be designed and produced very rapidly and can 
be used for large-scale vaccine production, which makes them attractive vaccine candidates in the face 
of an emerging pandemic outbreak.  
Various vectors are tested in the context of viral vector vaccines, of which Modified Vaccinia virus 
Ankara (MVA), discussed in this review, and adenovirus vectors are most prominent candidates. 
3. MVA 
3.1. The Development of the Attenuated Vaccinia Virus Strain MVA 
Modified Vaccinia virus Ankara (MVA) was derived from Chorioallantois Vaccinia virus Ankara 
(CVA) through serial passaging in chicken embryo fibroblasts (CEF) [69,70]. From 1968–1985, the 
Bavarian State Vaccine Institute produced MVA as a human smallpox vaccine. The application of this 
MVA vaccine was successful to increase the safety of the conventional smallpox vaccination as 
documented by the absence of any serious adverse event in large field trials involving more than 
120,000 individuals in Germany [71].  
The serial passage of MVA in primary and secondary CEF cultures resulted in major deletions in 
the viral genome and many mutations that affected most known vaccinia virus (VACV) virulence and 
immune evasion factors [72–74]. Consequently, MVA replication is highly restricted to avian cells and 
the virus is unable to produce infectious progeny in most cells of mammalian origin [75–77].  
3.2. Advantages of MVA as Viral Vector  
The host cell restriction of MVA is associated with a late block in the assembly of viral particles in 
non-permissive cells. This phenotype is rather exceptional among poxviruses with host range 
deficiencies, which are usually blocked prior to this stage during the abortive infection in mammalian 
cells [78–80]. Non-replicating MVA allows for unimpaired synthesis of viral early, intermediate and 
abundant late gene products, which supported its development as safe and particularly efficient viral 
vector [77]. Moreover, the biological safety and replication deficiency of MVA has been confirmed in 
various in vivo models, including avian species and animals with severe immunodeficiencies [81–84]. 
Therefore, recombinant MVA viruses as genetically modified organisms can be used under conditions 
of biosafety level 1 in most countries, provided that innocuous heterologous gene sequences are 
expressed. The latter attribute is an important advantage compared to replication competent poxvirus 
vectors (BSL 2 organisms) and other viral vectors and has certainly contributed to the increasing use of 
recombinant MVA in clinical testing.  
To deliver heterologous antigens with MVA as vector vaccine, the target gene sequences are 
transcribed under the highly specific control of poxviral promoters that are only recognized and 
activated by virus encoded enzymes and transcription factors. Recombinant genes are only transiently 
expressed after the infection with non-replicating MVA. Since there is no survival of MVA infected 
host cells it can be assumed that full clearance of recombinant virus and recombinant DNA occurs 
within days after vaccine administration. Despite the transient production of heterologous proteins 
MVA vector vaccines are able to elicit high levels of antigen-specific humoral and cellular immune 
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responses as demonstrated with the first MVA candidate vaccine delivering influenza antigens [85] 
(for review see [86]). It is of note that even for activation of antigen-specific CD8
+
 T cell responses, 
the delivery of stable proteins might be advantageous compared to immunogens that were designed for 
rapid intracellular degradation [87–89]. This seems to suggest that MVA-delivered proteins can be 
efficiently presented via both endogenous and cross-presentation pathways of MHC class I antigen 
processing (for review see [90]). 
Another characteristic of MVA vaccines is their surprising level of immunogenicity and protective 
capacity when compared to replicating VACV vector vaccines expressing the same recombinant 
genes [85,91,92]. Replication competent vectors, because of their capacity to amplify in vivo, could be 
expected to infect more target cells and produce higher amounts of antigen per immunization than the 
non-replicating MVA vectors. Nevertheless, the efficacy of the MVA vaccinations compared 
favorably to the outcome of immunizations with replication competent VACV vectors in mice and 
non-human primates. These observations may be best explained by the capacity of MVA to readily 
activate various components of the host innate immune system, most probably because of the lack of 
many immune evasion factors encoded by wild-type VACV [93–100]. Thus, unlike other VACV 
strains MVA does not produce the soluble virus proteins that function as receptor-like inhibitors of 
type I and type II interferons, tumor necrosis factor and chemokines [93]. Moreover, MVA infection 
can be sensed by multiple intracellular host detection mechanisms resulting in the production of 
interferons, inflammatory cytokines and chemokines [95]. Here, it is noteworthy that MVA has lost 
several of the VACV inhibitors targeting intracellular signaling pathways, e.g., the host NF-κB 
activation. In consequence, in vivo infection with MVA but not other VACV strains can trigger the 
rapid immigration of monocytes, neutrophils and CD4
+
 lymphocytes to the site of inoculation [99]. 
These intrinsic immunostimulating activities suggest that the use of additional adjuvant systems 
together with MVA might be dispensable for most vaccine applications. Finally, the continuing 
advances in genetic engineering, process development, large-scale manufacturing and MVA-specific 
immune monitoring have brought recombinant MVAs into clinical trials at an increasing scale [101–103]. 
The successful development of an MVA-based next generation vaccines against smallpox licensed in 
Europe and Canada has also contributed to this substantial groundwork for the development of future 
recombinant MVA vaccines [104]. 
4. MVA as an Influenza Vaccine 
As indicated above, MVA holds great promise as viral vaccine vector. It has been tested as 
candidate vaccine against influenza in several studies and the results of these studies are summarized 
here (Table 1). It has been suggested that the efficacy of vector vaccines could be hampered by the 
pre-existing immunity to the vector [105]. However, it has been demonstrated that with MVA this is 
not an issue, since with MVA, protective immunity could be induced against influenza in the presence 
of pre-existing vector immunity [106]. 
  




4.1.1. Vaccines against A/H5N1 Viruses 
Highly pathogenic avian influenza viruses of the H5N1 subtype cause mainly endemic outbreaks in 
poultry. Since the first human case of infection with an avian A/H5N1 influenza virus in 1997,  
over 650 cases have been reported of which 386 had a fatal outcome [107]. The circulation of A/H5N1 
viruses in poultry in several geographic regions continues to pose a threat to public health. A pandemic 
outbreak with this virus is still feared since it has been demonstrated that a handful of mutations are 
sufficient for these viruses to become transmissible between mammals [3,108]. The development of 
efficacious H5N1 vaccines is complicated by the co-circulation of viruses that belong to various 
antigenically distinct clades. Ideally, a novel vaccine induces antibodies that cross-react with A/H5N1 
viruses from multiple clades. 
Several recombinant MVA vaccines expressing an HA gene of various A/H5N1 viruses have been 
constructed and tested in various animal models [109]. MVA expressing the HA gene of influenza 
virus strain A/Vietnam/04 (MVA-HA-VN/04) induced strong antibody responses that cross-reacted 
with other viruses to some extent and protected mice from infection with homologous and 
heterologous A/H5N1 viruses [110,111]. MVA-HA-VN/04 induced superior protective immunity  
in mice to the homologous and heterologous H5N1 viruses compared to MVA expressing HA  
genes of A/H5N1 viruses A/Hong Kong/156/97, A/Indonesia/5/05, A/turkey/Turkey/1/2005, 
A/Chicken/Egypt/3/2006 or A/Anhui/1/2005 [111]. MVA-HA-VN/04 was also tested in non-human 
primates. Two immunizations with 10
8
 PFU protected cynomolgus macaques against infection with 
influenza viruses A/Vietnam/1194/04 and A/Indonesia/5/05 [112,113]. MVA-HA-VN/04 also proved 
to be immunogenic in chickens and afforded protection against infection [83]. The favorable outcome 
of preclinical testing of MVA-HA-VN/04 prompted the further clinical testing of this vaccine 
candidate in an ongoing phase I/II trial. 
To assess whether protective immunity also could be achieved with lower doses of MVA, dose 
finding was performed in mice with MVA-HA-VN/04. Interestingly, two immunizations with a dose 
as low as 10
4
 PFU were sufficient to induce protective immunity against infection with homologous 
and heterologous viruses. However, a dose of ≥10
5
 PFU was required for the induction of sterile 





 PFU resulted in protection from disease, albeit no sterile immunity was achieved [114]. 
These data indicate that in case of a pandemic, when large numbers of vaccine doses need to be 
produced in a short period of time, protective immunity against H5N1 viruses can be induced with one 
or two low doses of MVA. 
4.1.2. MVA-Based Vaccines against H1N1 Viruses 
In order to evaluate an MVA-based vaccine against the A/H1N1 virus that caused the pandemic of 
2009, the HA gene of a prototypic strain was cloned into MVA (MVA-HA-Ca/09). Mice vaccinated 
with MVA-HA-Ca/09 were protected from infection with a 2009 pandemic A/H1N1 influenza virus. 
Protection correlated with the induction of virus neutralizing antibodies and virus-specific T cells [115]. 
In addition, cross-protective immunity against some but not all swine A/H1N1 influenza viruses was 
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induced [116]. Thus, the MVA-HA-Ca/09 vaccine induces, to some extent, intrasubtypic immunity 
in mice. 
The MVA-HA-Ca/09 vaccine was also tested in ferrets. One immunization afforded only modest 
protection, but a second immunization induced robust antibody titers that reduced the virus replication 
after challenge infection with influenza virus A/Netherlands/602/09 (H1N1pdm09). However, full 
sterile immunity was not achieved, which may be related to the route of administration and/or dose of 
challenge virus [117]. Taken together, these data indicated that an MVA-based vaccine would have 
been able to induce protective immunity against the virus that caused the pandemic of 2009, although 
the extent of cross-protection against unrelated H1N1 viruses may have been limited. 
4.2. MVA-HA+NP 
In order to elicit both virus-specific antibodies and T cell responses with a single vaccine, 
recombinant MVA expressing both the HA and NP genes have been constructed. MVA expressing 
both NP and HA genes derived from influenza virus A/Puerto Rico/8/34 induced protective antibody 
and CTL responses against a homologous or heterologous infection in mice [85,118]. Other  
MVA-HA+NP vaccines have been prepared with HA genes obtained from A/California/04/2009 
(H1N1pdm09) (MVA-HA1+NP) or A/Vietnam/1203/2004 (H1N1) (MVA-HA5+NP). The use of 
MVA-HA1+NP induced cross-protective immunity against infection with the homologous pandemic 
H1N1 strain, an unrelated H1N1 strain and an H5N1 influenza virus. Furthermore, this vaccine 
afforded partial protection against a challenge with H3N2 influenza viruses. Thus, this recombinant 
MVA, expressing both the HA gene of an H1N1pdm09 virus and a highly conserved NP gene, induces 
heterosubtypic immunity. In contrast, MVA-H5+NP induced only protection against H5N1 virus and 
the pandemic H1N1 strain [106]. 
4.3. MVA-NP+M1 
To design an MVA-based vaccine that aims at the induction of virus-specific T cell responses only, 
recombinant MVA was constructed that expresses the genes encoding the relatively conserved internal 
structural proteins NP and M1. The MVA-NP+M1 vaccine has been tested in phase I and phase IIa 
clinical trials. The vaccine induces mainly virus-specific CD8
+
 T cells, which can be detected one 
week after intramuscular immunization [119] and induced protective immunity against an 
experimental infection one month after vaccination [120]. The vaccine was not only tested in healthy 
adults, 18–45 years of age, but also in people over 60 years of age. It was shown that the vaccine could 
safely be administered to the elderly [121]. 
Different vaccination strategies have been investigated [122,123]. It seems that priming with an 
adenovirus vector expressing NP and M1 and a subsequent boost with MVA expressing the same 
antigens induces higher levels of protective T cells than vaccination with either of the vectors 
alone [123,124]. The strongest T cell responses were obtained after intramuscular administration 
(adenovirus vector) and intranasal or intramuscular administration (MVA) compared to intradermal 
injection [123]. Intramuscular immunization is preferred because the vaccine is easy to administer and 
there is an optimal balance between immunogenicity and side effects. In addition, combinations of 
priming with MVA-NP+M1 and boosting with a HA-containing component have been tested, since the 
Viruses 2014, 6 2744 
 
 
MVA potentiates the second immunization [125,126]. Priming with MVA-NP-M1 and boosting with 
the trivalent influenza vaccine resulted in higher levels of total IgG but did not affect the number of 
IFNy-producing T cells when compared to vaccination with MVA alone. The combination vaccination 
strategy protected mice from a heterologous challenge infection six months after immunization [125].  
4.4. MVA Expressing Other Combinations of Influenza Virus Proteins 
In order to develop a universal influenza vaccine, various recombinant MVAs expressing a variety 
of conserved antigens derived from an A/H5N1 influenza virus were constructed. These antigens 
include NP, PB1, M1, M2, the HA stalk-domain, HA-stalk combined with NP, HA-stalk in 
combination with four repeats of M2e derived from H5N1, H9N2, H7N2 and H1N1 viruses and  
HA-stalk+4xM2e+NP. Mice were immunized twice with the respective MVA vaccines and 
subsequently infected with influenza virus subtypes with pandemic potential: H5N1, H7N1 or mouse 
adapted H9N2. MVA expressing NP, HA-stalk+NP or HA-stalk+4xM2e+NP induced heterosubtypic 





 T cells [127]. All the other MVA vaccines tested, MVA-HA-stalk, MVA-HA-stalk+M2e, 
MVA-M1, MVA-M2, MVA-PB1, failed to induce protective immunity. Interestingly, vaccination with 
MVA-M1 predisposed for more severe disease upon challenge infection of the mice, although the 
difference in survival rates with the naïve control group was not statistically significant [127]. Thus, 
MVA is widely used for the development of influenza vaccine, which shows encouraging results. The 
vector holds great promise as a vaccine platform for respiratory viruses in general. 
Table 1. Overview of MVA-based influenza vaccines. 
MVA vaccine Response Model Protective efficacy after challenge Literature 
MVA-NA-Ca/09 B cells mice Partial homologous protection [115] 
MVA-HA-HK/97 B cells mice Homologous protection [110] 
MVA-HA-VN/04 B cells 
mice Cross-clade protection [106,110,111] 
chickens Homologous protection [83] 
macaques Cross-clade protection [38,113] 
MVA-HA-IN/05 B cells mice Cross-clade protection [111] 
MVA-HA-TT/05 B cells mice Partial cross-clade protection [111] 
MVA-HA-AN/05 B cells mice Partial cross-clade protection [111] 
MVA-HA-CE/06 B cells mice Partial cross-clade protection [111] 
MVA-HA-Ca/09 B cells 
mice 
Homologous protection and to some 
extent heterosubtypic protection 
against swine viruses 
[115,116] 
ferret Intrasubtypic protection [117] 
MVA-HAstalk B cells mice No protection [127] 
MVA-HAstalk/M2e B cells mice No protection [127] 
MVA-
HAstalk/M2e+NP 
B cells and T 
cells 
mice Heterologous protection [127] 
MVA-HAstalk+NP 
B cells and T 
cells 
mice Heterologous protection [127] 
MVA-HA+NP 
B cells and T 
cells 
mice Homologous protection [85,106,118] 
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Table 1. Cont. 
MVA vaccine Response Model Protective efficacy after challenge Literature 
MVA-NP 
B cells and T 
cells 
mice Heterologous protection [127] 
MVA-NP+M1 T cells 
mice Partial heterologous protection* [123,125] 
chickens Heterologous protection* [124,125] 
pigs Not tested with challenge [125] 
humans Intrasubtypic protection, safe in elderly [119–122,126] 
MVA-M1 ** mice No protection [127] 
MVA-M2 ** mice No protection [127] 
MVA-PB1 
 










HA: Homologous protection 
NP: Partial homologous protection 
Literature: 
[128] 
* In combination with Adenovirus vaccine. ** No protective antibody response or T cell response measured. 
5. MVA-Based Vaccine against Other Respiratory Diseases 
5.1. Respiratory Diseases Caused by Viruses of the Paramyxoviridae Family 
Important viruses in the Paramyxoviridae family include the human parainfluenza viruses (PIV), 
human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). These pathogens are 
transmitted via the respiratory route and all are causing agents of acute respiratory tract infections in 
humans, particularly young children, elderly and the immunocompromised. Infections with these 
viruses are among the leading reasons for pediatric hospitalizations (for review see [129–131]). At 
present, there are no licensed vaccines for effective prevention of these infections, which has spurred 
the evaluation of first recombinant MVA vaccines against PIV and RSV.  
Recombinant MVA co-producing the fusion (F) and hemagglutinin-neuramidase (HN) proteins of 
PIV3 have been generated for preclinical testing in animal models [132]. In the cotton rat model, 
recombinant MVA elicited high levels of PIV-specific antibodies upon immunization by intramuscular 
or intranasal application. Upon challenge, MVA-HN was more efficient in inducing protection as 
determined by a substantial reduction of PIV loads in the nasal turbinates and lungs. This result 
favorably compared to responses achieved with an attenuated live PIV candidate vaccine. Furthermore, 
when used in rhesus macaques the recombinant MVA vaccines also induced protection against PIV 
challenge, although intranasal vaccinations could not completely prevent infections of the upper 
respiratory tract [133,134].  
First generation candidate MVA vaccines against RSV expressed recombinant gene sequences 
encoding for either the RSV fusion protein (F) or the glycoprotein (G) or both envelope antigens 
together [135]. In mice, all recombinant MVA induced RSV-specific antibodies and levels of MVA 
vaccine induced circulating antibodies were even higher than those found after experimental RSV 
infection. A follow-up study with these MVA vectors in a mouse model also demonstrated the 
induction of strong RSV-specific T cell responses, resulting in clearance of RSV from the lungs of the 
vaccinated animals, although it also associated with weight-loss in vaccinated animals [136]. An 
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enhancement of RSV-mediated lung eosinophilia was not seen upon challenge infection of MVA 
vector vaccinated animals. A parallel immunization study in infant cynomolgus macaques also 
suggested that vaccination with recombinant MVA did not predispose for an RSV associated 
immunopathology [137]. However, the combined intramuscular/intranasal immunization of these 
infant (<1 year old) macaques with the recombinant MVA failed to provide protection against RSV 
replication in the lower respiratory tract.  
To evaluate the safety and efficacy of new approaches in RSV vaccine development the infection of 
cattle with bovine RSV (bRSV) provides an excellent alternative model using a highly related 
pathogen in its natural host [138]. Recombinant MVA delivering bRSV F and G glycoprotein antigens 
(MVA/bRSV) were tested to protect calves against bRSV challenge [139]. Intramuscular vaccination 
of calves with MVA/bRSV induced bRSV specific IgG antibody and CD8
+
 T cell responses, but no 
detectable IgE antibodies. Upon challenge with bRSV the MVA/bRSV vaccinated calves compared to 
control animals demonstrated less severe lower respiratory tract symptoms, reduced pulmonary virus 
loads and no signs of bRSV-associated immunopathology (eosinophilic infiltrations). However, 
complete protection against bRSV infection or replication was not achieved.  
Overall, these previous studies suggested the safety and at least partial efficacy of first generation 
recombinant MVA vaccines against PIV or RSV. Other applications of recombinant MVA including 
mucosal delivery or the use of prime-boost strategies may contribute to further improve the 
effectiveness of preventive immunization against these respiratory diseases.  
5.2. Respiratory Diseases Caused by Emerging Coronaviruses 
In the last decade, two new beta coronaviruses have been transmitted from animal reservoirs 
(probably bat species) to humans causing major acute respiratory diseases associated with high 
mortality rates, severe acute respiratory syndrome coronavirus (SARS-CoV) and, more recently, 
Middle East respiratory syndrome coronavirus (MERS-CoV) [140,141] (for review see [142]). At 
present, there are no vaccines available which are approved for emergency use in humans to prevent 
either SARS-CoV or MERS-CoV infections. In 2004, about one year after the recognition of 
SARS-CoV in humans, recombinant MVA expressing the spike (S) protein, considered a key 
component of coronavirus-specific vaccines, was generated and demonstrated to elicit virus 
neutralizing antibodies in mice [143]. Also, another recombinant MVA vaccine producing SARS-CoV 
S antigen was found to induce high level (neutralizing) antibody responses in mice, rabbits and rhesus 
macaques [144]. Moreover, in the monkey model two immunizations with the recombinant MVA 
prevented replication of SARS-CoV upon respiratory challenge infection. Similarly, within the year of 
the appearance of MERS-CoV, a first candidate MVA vector vaccine producing the S glycoprotein of 
MERS-CoV (MVA-MERS-S) was obtained [145]. BALB/c mice were intramuscularly (i.m.) 
vaccinated with 10
8
 PFU MVA-MERS-S. Single administration of the MVA-MERS-S vaccine already 
induced low levels of virus-neutralizing antibodies in all animals tested. After booster immunization 
all vaccinated animals produced high levels of circulating antibodies that neutralized MERS-CoV. In 
contrast, neutralizing antibodies were not detected in sera from control animals and the specificity of 
the induced response was confirmed by the absence of detectable neutralization against SARS-CoV. 
These data support further evaluation of MVA-MERS-S as candidate emergency vaccine. In general, 
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the swift application of recombinant MVA in response to the appearance of SARS-CoV or  
MERS-CoV demonstrates the suitability of this vector system to readily respond to potential threats of 
suddenly emerging infectious diseases. 
6. Future Perspectives 
MVA has great potential as a rapid response vaccine platform for newly emerging virus infections. 
Established standard protocols allow rapidly obtaining recombinant MVA (rMVA) which are suitable 
for clinical evaluation (for review see [146]). This can be done by infection of CEF with fully 
characterized non-recombinant MVA seed virus and subsequent transfection of vector plasmid DNA 
containing the target gene of interest. Through homologous recombination, the heterologous gene 
sequences are inserted in the viral genome. The rMVA is clonally selected and amplified by serial 
passaging on CEF derived from certified embryonated eggs of specific pathogen free (SPF) chickens. 
The ideal process from a human case of infection with a novel respiratory virus to the construction and 
isolation of a candidate rMVA takes 6–12 weeks (Figure 1).  
In order to produce enough vaccine doses for a large-scale immunization campaign, large bulks of 
tissue culture are required. The use of CEF is well established in vaccine manufacturing. Primary 
CEFs are readily prepared from embryonated eggs without need for further amplification and, as 
known from the production of seasonal influenza vaccines, millions of eggs can be obtained and 
handled within days. CEF can be produced at a large scale and cryopreserved for a later time point. 
However, cryopreservation impacts the quality of the cells. Therefore, especially in the context of 
pandemic preparedness, continuous cell lines that allow for efficient MVA propagation, such as the 
duck cell lines AGE1.CR and AGE1.CR.pIX [147], would be more beneficial.  
Figure 1. Ideal timeline for construction of an MVA-based vaccine after a human case of 
infection with a novel respiratory virus. Influenza virus is used as an example. (1) After the 
emergence of a novel respiratory virus with the ability of infecting humans, (2) the virus is 
isolated (3) and the sequence of a target gene of interest is obtained within a week.  
(4) Subsequently, the gene of interest is cloned or simply synthesized and subcloned into 
an MVA shuttle vector plasmid. (5) This shuttle vector is then transfected in cells infected 
with MVA. Through homologous recombination the gene of interest is inserted into the 
MVA genome. (6) By serial plaque passages on CEF, a good laboratory practice (GLP) 
compliant rMVA is clonally isolated . The process from cloning to obtaining the rMVA 
takes about 6–12 weeks. 
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After generation of the rMVA, the vector vaccine needs to be validated in vitro to verify genetic 
stability, antigen expression and unimpaired growth capacity. Subsequently, in vivo experiments in 
pre-clinical models, e.g., mice, ferrets and/or macaques, are performed to determine the 
immunogenicity, usually testing various dosages and routes of administration, and possibly to obtain 
efficacy data. If successful in the pre-clinical phase, the vaccine is ready to be tested in humans. So far 
no MVA-based vaccine is registered and marketed for human use, but numerous vaccines are being 
tested in clinical trials [103]. In a phase I clinical trial, the safety of vaccine administration is tested. 
During phase II, safety and efficacy are further assessed, often involving various study populations. In 
phase III, the safety and efficacy are confirmed in large study groups. If the vaccine is successful 
during the different phases of the clinical trial, it can be registered for common use (Figure 2).  
However, there are some pitfalls in the development of a novel recombinant MVA vaccine, which 
might take precious time at the verge of a pandemic. First of all, it takes time to develop suitable 
animal models for newly emerging respiratory infections. Second, for each new vaccine, antigen 
potency and purity assays need to be developed for the appropriate quality assessment of the MVA 
vaccine preparations. Third, each new rMVA virus is a new biological entity. Therefore, each new 
vaccine must be tested thoroughly. However, in the case of a severe pandemic there would likely be no 
time to go through all the phases of clinical trials. Furthermore, combination vaccination strategies, 
e.g., priming with an adenovirus vector and boosting with an MVA vaccine, will lead to complicated 
regulatory procedures because two distinct biological entities need to be approved. Fourth, even 
though all the hands-on development work can be done rapidly, non-clinical safety testing, 
e.g., toxicity studies and ethics approval for animal experiments and clinical trials, and registration of 
the vaccine always depend on external parties, which could substantially slow down the development. 
Finally, also immunity to the vector, e.g., preexisting from smallpox vaccination, needs to be 
considered. However, studies have shown that even after multiple immunizations rMVA is still able to 
induce foreign antigen-specific immune responses in the presence of MVA-specific antibodies [106].  
Figure 2. Ideal timeline for evaluation of a novel MVA-based vaccine. (1) A newly 
developed rMVA vaccine (2) is tested in vitro to assess correct gene insertion and 
protein expression in rMVA infected cells, e.g., by Western Blot or flow cytometry. 
(3) Subsequently, the vaccine immunogenicity and efficacy is tested in mice, ferrets and/or 
macaques. (4) If the MVA-based vaccine is successful in the pre-clinical tests, the vaccine 
is tested in phase I, II and III clinical trails. (5) Finally, when the vaccine has proven safe 
and effective, it can be filed for market authorization. 
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In addition to these practical issues, there are regulatory issues that need to be addressed. So far, 
only one guideline for the quality and (non-)clinical aspects of live recombinant viral vectors 
exists [148]. In the case of influenza, special procedures are in place in the European Union to speed 
up the authorization process for novel vaccines. In the case of a pandemic, the vaccine  
needs to become available as soon as possible. The normal procedure to approve a new vaccine  
takes 18–24 months, which obviously is too long for a novel vaccine in the case of influenza 
pandemics. Therefore, there are two procedures in place for authorization of pandemic influenza 
vaccines. The first one is the ‘mock-up procedure’, where a prototype vaccine is authorized. It is not 
possible to predict which strain will cause a pandemic. Therefore, a vaccine based on a strain that has 
the potential to induce a pandemic is developed and tested. This proof-of-principle vaccine is then 
registered. Once the viral strain that is actually causing a pandemic is identified, this can be included in 
the mock-up vaccine and approved quickly. Second, the ‘emergency procedure’ allows for fast-track 
approval of a vaccine after a pandemic already started. With such an emergency procedure, a vaccine 
can be approved in 70 days. MVA and other vector-based vaccines are not covered by these pandemic 
influenza vaccine registration procedures. So, even though a MVA-based vaccine can be developed 
and produced relatively quickly after a pandemic outbreak, the vaccine will not be available in time to 
prevent a widespread pandemic.  
7. Conclusions 
As described, recombinant MVA has many features to serve as an excellent platform for the 
production of emergency vaccines. As with all vector vaccines, the foreign antigens they encode can 
be expressed in their native conformation, and will be authentically processed and presented to the 
immune system. This allows for induction of balanced humoral and cellular responses to induce solid 
pathogen-specific immunity. In addition, there are MVA-specific benefits. MVA is extremely 
replication-deficient in mammalian host cells, mediates strictly transient expression of the 
heterologous target genes, and the virus is highly attenuated in all in vivo models tested. Therefore, 
rMVA vaccines have an excellent safety profile considering clinical use and protection of the general 
environment. Furthermore, the impact of pre-existing vector immunity is limited, especially when 
compared to other viral vectors such as adenovirus-based vaccines [149]. Finally, rMVA vaccines are 
expected to be very stable over time enabling shipment to and application in remote areas with limited 
cold-chain maintenance. 
Even though MVA-based emergency vaccines can be developed relatively quickly, there are still 
some hurdles to overcome. Practical issues as well as regulatory issues need to be addressed in order to 
develop this platform for optimal use against pandemic influenza and other (newly emerging) 
respiratory virus infections.  
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